TY - JOUR
T1 - Local treatment with electrochemotherapy of superficial angiosarcomas
T2 - Efficacy and safety results from a multi-institutional retrospective study
AU - Guida, Michele
AU - Campana, Luca Giovanni
AU - Curatolo, Pietro
AU - Strippoli, Sabino
AU - Bonadies, Antonio
AU - Grilz, G.
AU - Cabula, Carlo
AU - Rotunno, Roberta
AU - Bucher, Stefania
AU - Solari, Nicola
AU - Santoriello, A.
AU - Valpione, Sara
AU - Rossi, Carlo Riccardo
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Background: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. Methods: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. Results: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). Conclusions: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246–253. © 2016 Wiley Periodicals, Inc.
AB - Background: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. Methods: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. Results: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). Conclusions: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246–253. © 2016 Wiley Periodicals, Inc.
KW - bleomycin
KW - drug delivery systems
KW - electrochemotherapy
KW - hemangiosarcoma
KW - local
KW - neoplasm recurrence
KW - vascular neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84978517828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978517828&partnerID=8YFLogxK
U2 - 10.1002/jso.24287
DO - 10.1002/jso.24287
M3 - Article
VL - 114
SP - 246
EP - 253
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 2
ER -